Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 8/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | JAK1 | P23458 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4911230 | 0.88 | TSHR (0.47) | RORCKMT2AALKJAK2JAK1 | |
| SCHEMBL16434707 | 0.88 | RORC (0.45) | RORCKMT2ASLC6A3ALKHDAC2 | |
| SCHEMBL16434822 | 0.88 | RORC (0.45) | RORCKMT2ASLC6A3ALKHDAC2 | |
| SCHEMBL16423222 | 0.86 | RORC (0.46) | RORCKMT2ASLC6A3HDAC2HDAC1 | |
| SCHEMBL16422384 | 0.86 | ALK (0.48) | RORCKMT2ASLC6A3ALKHDAC2 | |
| SCHEMBL4919416 | 0.86 | ALK (0.48) | RORCKMT2ASLC6A3ALKHDAC2 | |
| SCHEMBL4926305 | 0.86 | ALK (0.48) | RORCKMT2ASLC6A3ALKHDAC2 | |
| SCHEMBL4916837 | 0.85 | RORC (0.44) | RORCKMT2AHDAC2HDAC1MEN1 | |
| SCHEMBL4924425 | 0.85 | RORC (0.44) | RORCKMT2AHDAC2HDAC1MEN1 | |
| SCHEMBL4666899 | 0.84 | KMT2A (0.48) | KMT2ASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | ANDREWS MARK DAVID | 2008-10-30 | — | — | US | disclosed |
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | ANDREWS MARK DAVID | 2008-10-30 | — | — | US | disclosed |
| US-20080234280-A1 | Use of Mc4 Receptor Agonist Compounds | MCMURRAY GORDON | 2008-09-25 | — | — | US | disclosed |
| US-20080234280-A1 | Use of Mc4 Receptor Agonist Compounds | MCMURRAY GORDON | 2008-09-25 | — | — | US | disclosed |
| US-20080234280-A1 | Use of Mc4 Receptor Agonist Compounds | MCMURRAY GORDON | 2008-09-25 | — | — | US | disclosed |
| WO-2007015162-A1 | PIPERIDINOYL-PYRROLIDINE AND PIPERIDINOYL-PIPERIDINE COMPOUNDS | PFIZER LIMITED (GB) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007015157-A2 | MC4R-AG0NISTS FOR THE TREATMENT OF URINARY TRACT DYSFUNCTION | PFIZER LIMITED (GB) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | GPR4, GPR119, PRLHR | RORC 501/4885KMT2A 3354/4885SLC6A3 1030/4885 |
| US-20080234280-A1 | Use of Mc4 Receptor Agonist Compounds | MC4R, MC5R, GPR4 | RORC 1766/4885KMT2A 3266/4885SLC6A3 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.